THE BUDGET IMPACT OF DUORESP® SPIROMAX® (BUDESONIDE + FORMOTEROL FUMARATE DIHYDRATE) COMPARED WITH COMMONLY PRESCRIBED DRY POWDER INHALERS FOR THE MANAGEMENT OF ASTHMA AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN THE UNITED KINGDOM- IMPACT ...
Author(s)
Lewis A1, Blackney M1, Torvinen S2, Plich A2
1Covance Market Access, London, UK, 2Teva Pharmaceuticals Europe B.V., Amsterdam, The Netherlands
OBJECTIVES: DuoResp® Spiromax® (budesonide + formoterol fumarate dihydrate) is a fixed-dose combination (FDC) of inhaled corticosteroid (ICS) + long-acting beta agonist (LABA) in a novel dry powder inhaler (DPI). An economic model was developed to assess the budget impact of switching adult patients with persistent asthma and chronic obstructive pulmonary disease (COPD) from market-leading DPIs in the United Kingdom (UK) – Symbicort® Turbohaler® and Seretide® Accuhaler® – to DuoResp® Spiromax®
Conference/Value in Health Info
2015-05, ISPOR 2015, Philadelphia, PA, USA
Value in Health, Vol. 18, No. 3 (May 2015)
Code
PRS17
Topic
Economic Evaluation
Topic Subcategory
Budget Impact Analysis
Disease
Respiratory-Related Disorders